Cancer epigenetic therapy: recent advances, challenges, and emerging opportunities.

IF 3 4区医学 Q2 GENETICS & HEREDITY

Epigenomics Pub Date : 2025-01-01 Epub Date: 2024-11-27 DOI:10.1080/17501911.2024.2430169

Rajita Vatapalli, Alex P Rossi, Ho Man Chan, Jingwen Zhang

引用次数: 0

Abstract

Epigenetic dysregulation is an important nexus in the development and maintenance of human cancers. This review provides an overview of how understanding epigenetic dysregulation in cancers has led to insights for novel cancer therapy development. Over the past two decades, significant strides have been made in drug discovery efforts targeting cancer epigenetic mechanisms, leading to successes in clinical development and approval of cancer epigenetic therapeutics. This article will discuss the current therapeutic rationale guiding the discovery and development of epigenetic therapeutics, key learnings from clinical experiences and new opportunities on the horizon.

查看原文本刊更多论文

癌症表观遗传疗法：最新进展、挑战和新兴机遇。

表观遗传失调是人类癌症发生和维持的重要环节。本综述概述了对癌症表观遗传失调的了解如何为新型癌症疗法的开发带来启示。在过去的二十年里，针对癌症表观遗传机制的药物研发工作取得了长足的进步，并在癌症表观遗传疗法的临床开发和批准方面取得了成功。本文将讨论当前指导表观遗传疗法发现和开发的治疗原理、从临床经验中获得的主要启示以及即将出现的新机遇。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Epigenomics GENETICS & HEREDITY-

CiteScore

5.80

自引率

2.60%

发文量

审稿时长

>12 weeks

期刊介绍： Epigenomics provides the forum to address the rapidly progressing research developments in this ever-expanding field; to report on the major challenges ahead and critical advances that are propelling the science forward. The journal delivers this information in concise, at-a-glance article formats – invaluable to a time constrained community. Substantial developments in our current knowledge and understanding of genomics and epigenetics are constantly being made, yet this field is still in its infancy. Epigenomics provides a critical overview of the latest and most significant advances as they unfold and explores their potential application in the clinical setting.